AllSci News
Viridian’s Lumvoa becomes first to treat active and chronic thyroid eye disease with single label
Massachusetts-based Viridian Therapeutics (Nasdaq: VRDN) has received US FDA approval for Lumvoa (veligrotug-vvze), a full insulin-like growth factor-1 receptor (IGF-1R) antagonist for…
MSD explores regional pharma hub in Abu Dhabi to serve Gulf markets
The Department of Health – Abu Dhabi (DoH) and Merck & Co., Inc. (MSD) announced a collaboration to explore establishing a regional…
Shionogi taps real-world ALS data to strengthen edaravone’s market position post-approval
Japan-based Shionogi & Co., Ltd. (Tokyo: 4507) announced a continued partnership with the ALS/MND Natural History Consortium to access longitudinal, clinic-based real-world…
FDA Schedules Advisory Committee for Capricor's Deramiocel in Duchenne Muscular Dystrophy
San Diego-based Capricor Therapeutics (Nasdaq: CAPR) has announced that the US FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will...
FDA issues CRL to Sobi’s NASP over manufacturing failings
Sweden-based Swedish Orphan Biovitrum AB (STO: SOBI) disclosed on June 26, 2026, that the US FDA issued a Complete Response Letter (CRL)…
FDA delays Lantheus’ Ga-68 edotreotide approval over third-party manufacturing deficiencies
Lantheus Holdings said the US FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) seeking approval of LNTH-2501…
Nippon Shinyaku bets on Elixirgen's full-length dystrophin mRNA
Japan-based Nippon Shinyaku Co., Ltd. has signed an option agreement with Baltimore-based Elixirgen Therapeutics, Inc. granting it the right to acquire...
CHMP June 2026: Trofinetide reversal, avacopan revocation, and 6 new medicines advance toward EU approval
The EMA's Committee for Medicinal Products for Human Use concluded its June 2026 meeting with a series of consequential decisions: a rare reversal of a...
Idorsia secures USD 278m debt facility to extend runway as insomnia franchise scales
Switzerland-based Idorsia Pharmaceuticals Ltd (SWX: IDIA) confirmed the closing of a senior secured term loan facility of up to CHF 250 million...
Ligand raises USD 700m to fund USD 739m XOMA royalty acquisition
Jupiter, Florida-based Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced the closing of a USD 700 million offering of 0.00% convertible senior...
Boehringer Ingelheim taps Immunai’s AI to map T-cell targets across cancer and autoimmune disease
Boehringer Ingelheim and New York-based Immunai announced a multi-project discovery collaboration valued at up to USD 15 million, extending through 2027, focused…
Arcus enters immunology with first-in-human MRGPRX2 antagonist for atopic disease
Arcus Biosciences (NYSE: RCUS) has registered a first-in-human trial of AB102, an oral small-molecule antagonist of MRGPRX2 (Mas-related G-protein-coupled...
Nuvation Bio raises USD 250m in convertible notes
New York-based Nuvation Bio, Inc. (NYSE: NUVB) announced the pricing of an upsized convertible senior notes offering totaling USD 250 million, with proceeds...
Arrowhead launches mysterious RNAi candidate ARO-033 with undisclosed target and mechanism
Arrowhead Pharmaceuticals (Nasdaq: ARWR) has registered a first-in-human trial for ARO-033, an investigational subcutaneous agent that appears to be derived...
MaaT Pharma challenges EMA rejection of Xervyteg with re-examination request for aGvHD
France-based MaaT Pharma (Euronext: MAAT) has announced its intention to request a re-examination of the negative opinion issued by the European Medicines...
The AllSci Brief
Free, systematic R&D and deal news. Daily.